menu
    • menu
    [{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Envafolimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Alphamab \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Alphamab \/ Glenmark Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Jiangsu Alphamab

    Menu

    Jiangsu Alphamab

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jiangsu Alphamab

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Jiangsu Alphamab

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Envafolimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Glenmark Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Glenmark, Jiangsu Alphamab, and 3D Medicines Sign License Agreement for KN035

                            Details : Glenmark is responsible for developing, registering, and commercializing KN035 (envafolimab) outside of China for MSI-H or dMMR advanced solid tumors in previously treated adults.

                            Brand Name : KN035

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 25, 2024

                            Lead Product(s) : Envafolimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Glenmark Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth